Form 4 for RARE Ultragenyx Pharmaceutical Inc.
Accepted 2023-05-10 00:00:00 ET · period of report 2023-05-09 · accession 0001209191-23-028585 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-10 | 2023-05-09 | RARE | Huizenga Theodore Alan | SVP, CAO | M - OptEx | $21.00 | +3,000 | 30.7K | +11% | +$63.0K |
| D | 2023-05-10 | 2023-05-09 | RARE | Huizenga Theodore Alan | SVP, CAO | M - OptEx | $0.00 | -3,000 | 5,000 | -38% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-09 | M | A | 3,000 | $21.00 | 30,747 | D | — | — | (F1) Includes 227 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023. (F2) Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-05-09 | M | D | 3,000 | $0.00 | 5,000 | D | $21.00 · — to 2024-01-29 | 3,000 Common Stock | (F3) 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter. |